Insider Selling: Loxo Oncology Inc (LOXO) Insider Sells 10,000 Shares of Stock

Share on StockTwits

Loxo Oncology Inc (NASDAQ:LOXO) insider Naarden Jacob Van sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $166.32, for a total value of $1,663,200.00. Following the completion of the sale, the insider now directly owns 19,200 shares of the company’s stock, valued at approximately $3,193,344. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Naarden Jacob Van also recently made the following trade(s):

  • On Tuesday, August 14th, Naarden Jacob Van sold 10,000 shares of Loxo Oncology stock. The stock was sold at an average price of $159.34, for a total value of $1,593,400.00.
  • On Tuesday, July 10th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $183.50, for a total value of $565,547.00.
  • On Wednesday, June 20th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $178.14, for a total value of $549,027.48.

Shares of LOXO stock opened at $164.00 on Friday. Loxo Oncology Inc has a fifty-two week low of $71.45 and a fifty-two week high of $208.95. The company has a market capitalization of $5.02 billion, a price-to-earnings ratio of -30.89 and a beta of 2.25.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.15. The company had revenue of $42.60 million during the quarter, compared to the consensus estimate of $32.36 million. During the same quarter in the previous year, the firm posted ($0.94) EPS. equities research analysts forecast that Loxo Oncology Inc will post -0.47 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. New York State Common Retirement Fund lifted its position in Loxo Oncology by 1.6% in the first quarter. New York State Common Retirement Fund now owns 24,700 shares of the biopharmaceutical company’s stock valued at $2,850,000 after purchasing an additional 400 shares during the last quarter. Fortaleza Asset Management Inc. bought a new stake in Loxo Oncology in the second quarter valued at approximately $110,000. Voya Investment Management LLC lifted its position in Loxo Oncology by 0.4% in the second quarter. Voya Investment Management LLC now owns 186,422 shares of the biopharmaceutical company’s stock valued at $32,340,000 after purchasing an additional 661 shares during the last quarter. Swiss National Bank lifted its position in Loxo Oncology by 2.0% in the first quarter. Swiss National Bank now owns 36,400 shares of the biopharmaceutical company’s stock valued at $4,199,000 after purchasing an additional 700 shares during the last quarter. Finally, Xact Kapitalforvaltning AB lifted its position in Loxo Oncology by 28.4% in the first quarter. Xact Kapitalforvaltning AB now owns 3,165 shares of the biopharmaceutical company’s stock valued at $365,000 after purchasing an additional 700 shares during the last quarter. Hedge funds and other institutional investors own 97.46% of the company’s stock.

Several analysts have issued reports on LOXO shares. Zacks Investment Research lowered Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. BidaskClub raised Loxo Oncology from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 7th. Stifel Nicolaus cut their target price on Loxo Oncology from $225.00 to $217.00 and set a “buy” rating for the company in a research note on Friday, August 10th. Morgan Stanley upped their target price on Loxo Oncology from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, June 4th. Finally, JMP Securities upped their target price on Loxo Oncology from $182.00 to $221.00 and gave the stock a “buy” rating in a research note on Monday, June 4th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Loxo Oncology currently has a consensus rating of “Buy” and an average target price of $188.40.

About Loxo Oncology

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Recommended Story: Trading Strategy Methods for Individual Investors

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Codorus Valley Bancorp  Downgraded by BidaskClub to Sell
Codorus Valley Bancorp Downgraded by BidaskClub to Sell
AFLAC  Hits New 52-Week High at $47.27
AFLAC Hits New 52-Week High at $47.27
Middlesex Water  Sets New 1-Year High at $48.36
Middlesex Water Sets New 1-Year High at $48.36
Investors Title  Rating Lowered to Strong Sell at BidaskClub
Investors Title Rating Lowered to Strong Sell at BidaskClub
Exelixis  Stock Rating Lowered by BidaskClub
Exelixis Stock Rating Lowered by BidaskClub
Green Brick Partners  Rating Lowered to Sell at BidaskClub
Green Brick Partners Rating Lowered to Sell at BidaskClub


Leave a Reply

© 2006-2018 Ticker Report. Google+.